Format

Send to

Choose Destination
Cell. 2016 Jul 14;166(2):263. doi: 10.1016/j.cell.2016.06.049.

Gene Therapy for "Bubble Boy" Disease.

Author information

1
Cancer Center and Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA 02129, USA. Electronic address: hoggatt.jonathan@mgh.harvard.edu.

Abstract

Adenosine deaminase (ADA) deficiency results in the accumulation of toxic metabolites that destroy the immune system, causing severe combined immunodeficiency (ADA-SCID), often referred to as the "bubble boy" disease. Strimvelis is a European Medicines Agency approved gene therapy for ADA-SCID patients without a suitable bone marrow donor.

PMID:
27419862
DOI:
10.1016/j.cell.2016.06.049
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center